1. Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Issue 2 (21st January 2020) Authors: Bei, Di; Osawa, Mayu; Uemura, Shinji; Ohno, Tomoya; Gobburu, Jogarao; Roy, Amit; Hasegawa, Mayumi Journal: Cancer science Issue: Volume 111:Issue 2(2020) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Engineering nanomedicines for improved melanoma therapy: progress and promises. (November 2010) Authors: Bei, Di; Meng, Jianing; Youan, Bi-Botti C Journal: Nanomedicine Issue: Volume 5:Number 9(2010) Page Start: 1385 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Enzyme‐ and Transporter‐Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Issue 12 (10th October 2014) Authors: Shao, Jie; Markowitz, John S.; Bei, Di; An, Guohua Journal: Journal of pharmaceutical sciences Issue: Volume 103:Issue 12(2014:Dec.) Page Start: 3810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2. Issue 1 (22nd November 2022) Authors: Catlett, Ian M.; Aras, Urvi; Hansen, Lars; Liu, Yali; Bei, Di; Girgis, Ihab G.; Murthy, Bindu Journal: Clinical and translational science Issue: Volume 16:Issue 1(2023) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗